TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06475625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro™ or Orsiro_Mission™ stent
Description: Percutaneous coronary intervention with Orsiro™ or Orsiro_Mission™ stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro™ or Orsiro_Mission™ stent
Description: Percutaneous coronary intervention with Orsiro™ or Orsiro_Mission™ stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orsiro™ or Orsiro_Mission™ stent
Description: Percutaneous coronary intervention with Orsiro™ or Orsiro_Mission™ stents
Study: NCT00784134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
Study: NCT01901172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Daily for 5 days followed by 23 days rest per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Description: Single doses Days 1 and 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: posaconazole
Description: Multiple doses Days 8-14
Study: NCT04736355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, for 24 weeks
Study: NCT03584646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nokia GO Wearable StepTracker
Description: All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reminder
Description: Medication reminders are sent to participants in Arm 2 on a daily basis.
Study: NCT06015932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Participate in CBCSM group sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03584646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Check-in appointment with study team or provider
Description: Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
Study: NCT04528576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dragonfly mitral valve repair system
Description: With transesophageal echocardiographic guidance,implanting clip using Dragonfly mitral valve repair system
Study: NCT02241135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
Study: NCT00618540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age \<12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age \<12 months)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
Study: NCT03125382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carelink System
Description: Patients start to perform device data transmission through Carelink system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carelink System
Description: Patients start to perform device data transmission through Carelink system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In office standard visit
Description: Patients start or maintain in office standard visits

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In office standard visit
Description: Patients start or maintain in office standard visits
Study: NCT00130780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-surgical Treatment with Bevacizumab plus Chemotherapy
Description: On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Description: Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
Study: NCT03896841

Intervention type: OTHER
Intervention: Observation
Description: Ocular Findings Observations

Intervention type: OTHER
Intervention: Observation
Description: Ocular Findings Observations
Study: NCT00355914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Facet Joint Nerve Block
Description: Lumbar Facet Joint Nerve Block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Facet Joint Nerve Block
Description: Lumbar Facet Joint Nerve Block
Study: NCT00633854

Intervention type: PROCEDURE
Intervention: Ultrasound examination
Description: Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
Study: NCT03457246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-Pigment rich texture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hydrance optimale riche
Study: NCT02692742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myelo001
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
Study: NCT03812003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
Study: NCT03368833

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: 12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: 12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
Study: NCT04580303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Delivered via uniform grid injection techniques.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Delivered via uniform grid injection techniques.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Delivered via uniform grid injection techniques.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: collagenase clostridium histolyticum
Description: Delivered via uniform grid injection techniques.
Study: NCT00793286

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh fixation by staples
Description: Mesh fixation by staples

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mesh fixation by glue
Description: Mesh fixation by glue
Study: NCT01290224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scrambler therapy
Description: Undergo MC5-A therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sham intervention
Description: Undergo sham procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00521937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermagen®
Description: Weekly topical applications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermagen®
Description: Weekly topical applications
Study: NCT04588480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: BNT162b2 (intramuscular injection)
Study: NCT02241135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV7201 mRNA
Description: CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
Study: NCT04588480

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (intramuscular injection)
Study: NCT03553875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
Study: NCT02593396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride sustained-release
Description: Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
Study: NCT03399578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
Study: NCT03495284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato-based side dish
Description: Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain-based
Description: Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
Study: NCT01450124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boswellic acids (BOSWELAN)
Description: 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
Study: NCT02919176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Mirabegron 50 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 30 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron and Pioglitazone
Description: Mirabegron 50 mg/day and Pioglitazone 30 mg/day
Study: NCT03970590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTC Intervention
Description: An integrated peer narrative-based intervention (VIEW \> SELECT \> GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran\] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 6-month HTN management assessment text messages without narrative component
Study: NCT02886793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose
Study: NCT00853827

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg
Study: NCT03691428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wish Outcome Obstacle Plan
Description: 1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wish Outcome Obstacle Plan
Description: 1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if \[specified obstacle - when I feel impatient\], then I will \[specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly\] plan.
Study: NCT04072822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra and Zinc
Description: Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Matching placebo
Study: NCT03014596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assert
Description: The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
Study: NCT04420195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Tacrolimus
Description: Envarsus XR is an FDA-approved drug for the prophylaxis of organ rejection in de novo kidney transplant patients or in kidney transplant patients converted from IR tacrolimus when used with other immunosuppressants. Envarsus XR is a novel extended-release formulation of tacrolimus created using MeltDose technology. Envarsus XR is available in tablet form. It is available in 0.75, 1, and 4 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-Release Tacrolimus
Description: Historical cohort of 20 subjects who will be maintained on IR tacrolimus following transplant. Dosing will be converted on an individual basis (Capsules: 0.5 mg, 1 mg and 5 mg or Injection: 5 mg) . All patients will be initiated on IR tacrolimus either under the tongue (sublingual) or as a solution given through a tube placed through the nose into the stomach, which is standard of care for all lung transplant recipients.
Study: NCT01191463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mung Bean Meal
Description: 50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mung Bean Meal
Description: 50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guava
Description: A fresh Guava fruit will be provided raw (approx 100g fresh weight)
Study: NCT05399394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The induction phase of the treatment plan was designed to administer FOLFIRINOX protocol (oxaliplatin 85 mg/mq and irinotecan 180 mg/mq plus leucovorin 400 mg/mq followed by bolus fluorouracil (FU) 400 mg/mq on day 1, then FU 2,400 mg/mq as a 46-hour continuous infusion) every 14 days for four cycles. In the combined phase, concurrent chemotherapy consisted of weekly gemcitabine at the dose of 600 mg/mq.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by the Clinical Target Volume (CTV) with a safety margin to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied through cone-beam computed tomography systems (CBCT) for all patients to evaluate the precision of the set-up.